Anti-IL1 agents, which block the effect of the excessive load of IL1 manufactured due to lack of caspase inhibition by the mutant pyrin, have surpassed all other therapeutic options for colchicine-resistant FMF patients.9 Two drugs are currently available in Israel, anakinra and canakinumab, while the third, rilonacept, may shortly be available as well. The gene discussed is MEFV; the disease is familial Mediterranean fever.